Neuberger Berman Group
ABBV icon

Neuberger Berman Group’s AbbVie ABBV Stock Holding History

Neuberger Berman Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Buy
+8,000
New +$1.72M ﹤0.01% 1290

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Neuberger Berman Group's ABBV Position: Q2 2026 in Review

Neuberger Berman Group increased its AbbVie (ABBV) stake by 3.6% in Q2 2026, buying an estimated $9.54M and bringing the position to 1,279,175 shares worth $322M. The position accounts for 0.21% of the portfolio, ranked #87.

Neuberger Berman Group first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $490M in Q4 2023. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Neuberger Berman Group held 1,279,175 shares of AbbVie worth $322M as of Q2 2026.
  • Neuberger Berman Group bought 44,339 AbbVie shares in Q2 2026, an estimated $9.54M.
  • AbbVie made up 0.21% of Neuberger Berman Group's portfolio in Q2 2026, its #87 holding.
  • Neuberger Berman Group first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Neuberger Berman Group's AbbVie position peaked at $490M in Q4 2023.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.